Abstract
When treating schizophrenia and other psychotic disorders, clinicians often encounter the problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life. The uncertain oral drug taking habits may lead to relapses and rehospitalizations. Using second generation long acting injectables we have more possibilities to avoid these problems. This review attempts to present and describe the pharmacological background of the modern long acting injectables including patient cases where olanzapine pamoate long acting injectable provided remission and better quality of life for the patients.
MeSH terms
-
Administration, Oral
-
Adult
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use*
-
Benzodiazepines / administration & dosage
-
Benzodiazepines / adverse effects
-
Benzodiazepines / therapeutic use*
-
Delayed-Action Preparations / therapeutic use
-
Female
-
Humans
-
Hypnotics and Sedatives / adverse effects
-
Injections, Intramuscular
-
Male
-
Medication Adherence*
-
Middle Aged
-
Olanzapine
-
Psychotic Disorders / diagnosis
-
Psychotic Disorders / drug therapy*
-
Psychotic Disorders / psychology*
-
Recurrence
-
Schizophrenia / drug therapy
-
Schizophrenic Psychology
Substances
-
Antipsychotic Agents
-
Delayed-Action Preparations
-
Hypnotics and Sedatives
-
Benzodiazepines
-
Olanzapine